Technoview® LMW Control High

Technoview® LMW Control High is a plasma control with a high concentration (~1.1 IU/ml) of low molecular weight (LMW) heparin for use as a quality control sample in research measurements of low molecular weight heparin. It is optimized for use with anti-Xa chromogenic assays and is frequently used in conjunction with the Technoview® LMW heparin low and medium controls and the Technoview® LMW heparin calibrator set in the Technochrom® anti-Xa chromogenic assay.

Please consult the lot specific batch table provided with the controls for the exact concentrations in IU/mL of each control.

Stability after reconstitution: 18-25°C (open vial) / 48 hours, 2-8°C (closed vial) / 7 days, -20°C / 1 month.

Advantages

• 5 vials per kit- provides control set with a long shelf life
• Allows for the validation of calibration curves for the measurement of low molecular weight (LMW) heparin in plasma
• Optimized for use with anti-Xa (without exogeneous antithrombin) research assays

Control Set Composition

• 5 x 1 ml vials

Control material is lyophilized and prepared from pooled human citrated plasma supplemented with a high concentration of LMW heparin. The plasma contains stabilizers but no bactericide additives. It is calibrated against the International Standard preparation for LMWH, 01/608.

Background

Heparin is a widely used antithrombotic agent that can be administered via an intravenous or subcutaneous route. It is naturally occurring and typically derived from bovine or porcine tissue. The anticoagulant effect of this sulfated glycosaminoglycan results from its binding to antithrombin (AT), the major inhibitor of the coagulation cascade. Binding induces a conformational change in the AT molecule, which greatly accelerates the AT inhibition of several coagulation proteases. The accelerated inhibition of thrombin and Factor Xa by heparin is the primary basis for its anticoagulation properties.

Two forms of heparin are used therapeutically: unfractionated heparin (UFH), with an average molecular weight (MW) of 15,000 and low molecular weight heparin (LMWH), with a MW between 4,000 and 6,500. The lower MW results in LMWH acting primarily on Factor Xa, whereas UFH efficiently inhibits both thrombin and Factor Xa. Both heparin forms should be monitored. UFH can be measured with an aPTT or an anti-Xa chromogenic assay while LMWH should be measured using and anti-Xa chromogenic assay. Note that this control is for research use only in the US and Canada.